Impact of competitive inhibition and sequence variation upon the sensitivity of Malaria PCR by Bialasiewicz, Seweryn et al.
JOURNAL OF CLINICAL MICROBIOLOGY, May 2007, p. 1621–1623 Vol. 45, No. 5
0095-1137/07/$08.000 doi:10.1128/JCM.02145-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Impact of Competitive Inhibition and Sequence Variation upon the
Sensitivity of Malaria PCR
Seweryn Bialasiewicz,1,2* David M. Whiley,1,2 Michael D. Nissen,1,2,3 and Theo P. Sloots1,2,3
Queensland Paediatric Infectious Diseases Laboratory, Sir Albert Sakzewski Virus Research Centre, Royal Children’s Hospital and
Health Service District, Herston, Queensland, Australia1; Clinical Medical Virology Centre, University of Queensland, Brisbane,
Queensland, Australia2; and Microbiology Division, Queensland Health Pathology Service,
Royal Brisbane Hospital Campus, Brisbane, Queensland, Australia3
Received 19 October 2006/Returned for modification 29 November 2006/Accepted 15 February 2007
Real-time PCR assays for Plasmodium species utilizing universal and species-specific primers were com-
pared to investigate variables influencing decreased assay sensitivity. Sequence variation in oligomer targets
and competitive inhibition of dual-species templates in universal-primer mixes were found to decrease assay
sensitivity.
It has been estimated that at the end of 2004, 3.2 billion
people lived at risk of malarial infection (20). Annually, be-
tween 350 and 500 million clinical episodes occur, with the
majority being caused by Plasmodium falciparum or Plasmo-
dium vivax (20). Of particular concern is P. falciparum, which
causes the majority of malaria-related deaths, estimated to be
between 0.7 and 2.7 million per year (2, 20). Recent increases
in global human movement due to tourism, migrations, and
displacement through disasters or conflict (5, 8, 12) have co-
incided with an increased importation of malaria into regions
where the disease is not endemic (1, 7). For example, between
2002 and 2003, travelers and migrants who were born in areas
of malaria endemicity constituted 19% and 18% of people
moving into the United States and Australia, respectively (4,
17). In Australia, all four human Plasmodium species are rou-
tinely detected, with cases typically arising in migrants, travel-
ers, soldiers, and refugees (3, 13). Traditionally, light micros-
copy has been utilized in Plasmodium species detection;
however, the last decade has seen the introduction of nucleic
acid amplification-based diagnostic assays (9, 18), including
rapid real-time PCR methods (11, 14). Regardless of method,
we emphasize that diagnostic tools need to be able to ade-
quately detect and distinguish the malarial species, particularly
the highly pathogenic P. falciparum. The requirement for ad-
equate discrimination is further necessitated by the high inci-
dence of mixed-species malarial infections (up to 12%) (6, 10,
15). In this study, we utilized published real-time PCR meth-
ods to highlight the potential for sequence variation and com-
petitive inhibition to produce false-negative results by Plasmo-
dium species PCR methods.
Two sets of real-time PCR assays targeting the plasmodium
18S rRNA gene were compared for the detection of P. falcip-
arum, P. vivax, and Plasmodium ovale. Each of the real-time
PCR sets comprised three separate TaqMan PCR assays for
the detection of each of the three species. The first set (Peran-
TM, where TM refers to TaqMan) utilized primers and probes
previously described by Perandin et al. (11), while the second
set (Rouge-TM) used primer and probe sequences described
by Rougemont et al. (14). There were two key differences
between the Peran-TM and Rouge-TM methods. First, each
PCR targeted different sequences on the 18S gene of each
species. Second, the Peran-TM methods used species-specific
primers and probes, whereas the Rouge-TM methods used
species-specific probes with a single set of universal primers for
amplification of all three Plasmodium species. Briefly, in our
study, 119 blood specimens (with labeling preserving donor
anonymity) were obtained from immigrants from areas of ma-
laria endemicity and from subjects who returned from overseas
travel to areas of malaria endemicity and presented with clin-
ical features suggestive of malaria. Nucleic acids were ex-
tracted from each specimen using the High Pure viral nucleic
acid kit (Roche Diagnostics, Australia) by following the man-
ufacturer’s protocol. The original reaction conditions were
modified; PCR was performed using 25-l reaction mixtures
containing 5 l of nucleic acid extract, 10 pmol of each primer,
4 pmol of each probe, and 12.5 l of QIAGEN QuantiTect
Probe PCR master mix (QIAGEN, Australia). PCR cycling
was performed on a RotorGene 3000 cycler (Corbett Life
Science, Australia), with an initial activation at 95°C for 10 min
and 45 cycles of 95°C for 15 seconds and 60°C for 60 seconds.
Of the 119 specimens tested, 108 provided agreement be-
tween the results of the Peran-TM and Rouge-TM assays; 40
specimens were positive for P. falciparum, 50 were positive for
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TABLE 1. Sequence alignments illustrating mismatches with
assay oligonucleotides
Oligonucleotide or sample
(GenBank accession no.) Sequence
a
Peran-TM P. ovale probe..........CCTTTTCCCTATTCTACTTAATTCGCAATTCATG
Sample 15 (DQ845247).............CCTTTTCCCTTTTCTACTTAATTCGCTATTCATG
Peran-TM P. ovale
forward primer ........................TTTTGAAGAATACATTAGGATACAATTAATG
Sample 15....................................TTTTGAAGAATATATTAGGATGCATTATAGT
a Mismatched bases are underlined.
1621
 o
n
 O
ctober 21, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
P. vivax, 1 was positive for P. ovale, 4 were positive for both P.
falciparum and P. vivax, and 13 were negative by both proto-
cols. Of the 11 specimens providing discrepant results, 10 were
positive for both P. falciparum and P. vivax by the Peran-TM
method but were positive for only one species by the
Rouge-TM method (6 were positive for P. vivax and 4 were
positive for P. falciparum). The presence of both species was
confirmed for 9 of these 10 samples by utilizing a previously
described nested malaria PCR assay (16). One specimen was
positive for P. ovale by the Rouge-TM method but was nega-
tive by the Peran-TM method.
The specimen that produced a false-negative result in the
Peran-TM P. ovale assay provided a cycle threshold (CT) value
of 25 cycles in the Rouge-TM P. ovale PCR. Thus, a low
template load was not considered to be the source of the
false-negative result. An amplification product was not ob-
served upon gel electrophoresis of the Peran-TM P. ovale re-
action mix. Sequencing of the 18S sequence of this P. ovale
strain revealed two mismatches with the Peran-TM P. ovale
probe and seven mismatches with the Peran-TM P. ovale for-
ward primer (Table 1, sample 15). The concentration of mis-
matches at the 3 end of the forward primer was thus consid-
ered to have prevented PCR amplification.
Investigation of the mixed-species specimens indicated that
the relative concentrations of P. falciparum and P. vivax DNAs
determined the ability to detect one or both species in the
Rouge-TM assays. In the Peran-TM assays, the P. falciparum
and P. vivax PCR CT values differed by 6.9 to 16.7 cycles for the
specimens in which only one species was detected by the
Rouge-TM assays (Table 2, samples 1 to 10). Thus, assuming
that 3.3 cycles represent a 1-log difference in DNA loads, then
there was at least a 100-fold difference in the concentrations of
P. falciparum and P. vivax DNAs in these specimens. Notably,
the particular species detected by the Rouge-TM assays cor-
related with species predicted to be at their highest concen-
trations based on the Peran-TM CT values. In contrast, the
Peran-TM P. falciparum and P. vivax CT values differed by
only 0.3 to 4.1 cycles in the samples in which both species
were detected by the Rouge-TM methods (Table 2, samples
11 to 14).
To further investigate this phenomenon, we tested 10-fold
dilutions of quantified P. falciparum DNA spiked with static
amounts of quantified P. vivax DNA with both the P. falcip-
arum Peran-TM and Rouge-TM methods. In brief, the results
suggest that the Rouge-TM assays cannot reliably detect both
species in cases where there is a 10-fold difference in the
DNA loads. In contrast, the Peran-TM methods could reliably
detect both species even where the relative loads differed by at
least 100-fold (Table 3). Further investigation of the Rogue-TM
assay involving a comparison of the spiked and unspiked serial
dilutions showed reliable detection of the P. falciparum dilu-
tions in the absence of a competing P. vivax template (Table 3).
Similar Rouge-TM results were generated when P. vivax dilu-
tions were tested with and without static P. falciparum spikes
(data not shown). Furthermore, spiked and unspiked dilution
sets were run in both assays under the conditions originally
published in order to exclude the possibility of assay under-
performance, and results comparable to the aforementioned
data were observed (data not shown).
The limited capacity of the Rouge-TM methods to detect
mixed-species infections was most likely due to the previously
described mechanism of competitive inhibition caused by the
use of universal primer sequences (19). The three Rouge-TM
PCR assays used the same forward and reverse primers for the
amplification of all three Plasmodium species. This meant that
any of the species could be amplified in any of the three PCRs
even though the detection of only one species was facilitated by
a species-specific probe. Thus, if the concentration of DNA of
one species exceeded that of the DNA of another species, then
TABLE 2. Peran-TM assay CT values and Rouge-TM assay results
for the 14 specimens containing both P. falciparum and
P. vivax nucleic acidsa
Sample
Peran-TM CT value CT of
Peran-TM
Rouge-TM result
P. falciparum P. vivax P. falciparum P. vivax
1 33.5 () 24.0 () 9.5 ND () 25.3 ()
2 28.8 () 21.1 () 7.7 ND () 24.4 ()
3 34.3 () 16.3 () 18.0 ND () 20.7 ()
4 31.5 () 22.1 () 9.4 ND () 26.0 ()
5 33.7 () 17.0 () 16.7 ND () 23.6 ()
6 33.4 () 19.4 () 14.0 ND () 23.1 ()
7 18.7 () 33.7 () 15.0 18.4 () ND ()
8 25.0 () 32.2 () 7.2 23.0 () ND ()
9 23.7 () 30.6 () 6.9 22.7 () ND ()
10 19.4 () 27.4 () 8.0 17.5 () ND ()
11 22.5 () 23.9 () 1.4 20.8 () 29.8 ()
12 28.8 () 25.6 () 3.2 27.6 () 27.4 ()
13 23.6 () 23.3 () 0.3 22.3 () 27.2 ()
14 24.3 () 20.2 () 4.1 27.9 () 24.4 ()
a The success of assay detection for each species is indicated by “” (positive)
or “” (negative). ND, not detected.
TABLE 3. P. falciparum Rogue-TM and Peran-TM CT values for P. falciparum serial dilutions with and
without inclusion of a P. vivax DNA spikea
P. falciparum
dilution
P. falciparum DNA only P. falciparum DNA spiked with P. vivax DNA
Approx P. falciparum
copy no.
Rouge-TM
CT value
Peran-TM
CT value
Approx P. falciparum
copy no.
Approx P. vivax
copy no.
Rouge-TM
CT value
Peran-TM
CT value
Neat 10,000 20.9 20.5 10,000 100 21.6 19.4
101 1,000 24.2 24.3 1,000 100 24.5 23.0
102 100 27.7 28.1 100 100 29.0 26.3
103 10 31.7 31.3 10 100 ND 29.7
104 1 36.9 34.5 1 100 ND 32.2
105 0.1 ND ND 0.1 100 ND ND
a ND, not detected.
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the DNA at the greater concentration would amplify first and
subsequently monopolize the PCR.
Overall, the above results highlight the impact that sequence
variation and competitive inhibition can have on the success of
malaria PCR assays. However, these considerations can be
applied universally in the development of any nucleic acid
amplification method. Specifically, when developing and using
malaria nucleic acid amplification methods, laboratories both
in areas where malaria is endemic and in areas where it is not
endemic need to consider the importance of identifying mixed-
species infections, as well as the need for the careful design and
evaluation of primers and probes. Given the above-mentioned
findings, we underline the importance of utilizing conserved
species-specific oligonucleotides for the PCR detection of Plas-
modium species.
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